Follow the people · Insider
Huda Y. Zoghbi
Huda Y. Zoghbi files insider transactions with the SEC as a director of Regeneron Pharmaceuticals (REGN). We hold 2 disclosed purchases and sales filed since 12 September 2016, 1 of them in the last 90 days.
- Files forREGN
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure12 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 9 September 2016 — 10 August 2026Director · Regeneron Pharmaceuticals (REGN)90 Form 4 lines · source: SEC Form 4
Everything they disclosed
90 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 800 shares of Regeneron PharmaceuticalsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- ▼ sold on the open market 800 shares of Regeneron PharmaceuticalsSEC Form 412 August 2026Common Stock · traded 10 August 2026 · filed 12 August 2026
- exercised options over 800 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 412 August 2026Non-Qualified Stock Option (right to buy) · traded 10 August 2026 · filed 12 August 2026
- exercised options over 1,638 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 160 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 56 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 4 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- exercised options over 1,638 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 423 February 2026Non-Qualified Stock Option (right to buy) · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 49 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 50 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- exercised options over 1,638 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 423 February 2026Non-Qualified Stock Option (right to buy) · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 53 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 208 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 331 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 209 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 298 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- exercised options over 1,638 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 49 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 50 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 53 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 208 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 331 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 209 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 298 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 220 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 160 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 56 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 4 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- ▼ sold on the open market 220 shares of Regeneron PharmaceuticalsSEC Form 423 February 2026Common Stock · traded 19 February 2026 · filed 23 February 2026
- was granted 155 shares of Regeneron PharmaceuticalsSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- was granted 1,962 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 46 January 2026Non-Qualified Stock Option (right to buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 1,962 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 46 January 2026Non-Qualified Stock Option (right to buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 155 shares of Regeneron PharmaceuticalsSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- was granted 1,958 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 46 January 2025Non-Qualified Stock Option (right to buy) · traded 2 January 2025 · filed 6 January 2025
- was granted 166 shares of Regeneron PharmaceuticalsSEC Form 46 January 2025Common Stock · traded 2 January 2025 · filed 6 January 2025
- exercised options over 1,117 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 44 January 2024Non-Qualified Stock Option (right to buy) · traded 2 January 2024 · filed 4 January 2024
- was granted 1,607 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 44 January 2024Non-Qualified Stock Option (right to buy) · traded 2 January 2024 · filed 4 January 2024
- exercised options over 1,117 shares of Regeneron PharmaceuticalsSEC Form 44 January 2024Common Stock · traded 2 January 2024 · filed 4 January 2024
- ▼ sold on the open market 1,117 shares of Regeneron PharmaceuticalsSEC Form 44 January 2024Common Stock · traded 2 January 2024 · filed 4 January 2024
- was granted 135 shares of Regeneron PharmaceuticalsSEC Form 44 January 2024Common Stock · traded 2 January 2024 · filed 4 January 2024
- exercised options over 1,000 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 417 October 2023Non-Qualified Stock Option (right to buy) · traded 13 October 2023 · filed 17 October 2023
- exercised options over 1,000 shares of Regeneron PharmaceuticalsSEC Form 417 October 2023Common Stock · traded 13 October 2023 · filed 17 October 2023
- ▼ sold on the open market 1,000 shares of Regeneron PharmaceuticalsSEC Form 417 October 2023Common Stock · traded 13 October 2023 · filed 17 October 2023
- was granted 1,929 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 45 January 2023Non-Qualified Stock Option (right to buy) · traded 3 January 2023 · filed 5 January 2023
- was granted 165 shares of Regeneron PharmaceuticalsSEC Form 45 January 2023Common Stock · traded 3 January 2023 · filed 5 January 2023
- exercised options over 2,000 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 418 March 2022Non-Qualified Stock Option (right to buy) · traded 16 March 2022 · filed 18 March 2022
- exercised options over 2,000 shares of Regeneron PharmaceuticalsSEC Form 418 March 2022Common Stock · traded 16 March 2022 · filed 18 March 2022
- ▼ sold on the open market 2,000 shares of Regeneron PharmaceuticalsSEC Form 418 March 2022Common Stock · traded 16 March 2022 · filed 18 March 2022
- was granted 2,707 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 45 January 2022Non-Qualified Stock Option (right to buy) · traded 3 January 2022 · filed 5 January 2022
- was granted 191 shares of Regeneron PharmaceuticalsSEC Form 45 January 2022Common Stock · traded 3 January 2022 · filed 5 January 2022
- exercised options over 2 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 415 September 2021Non-Qualified Stock Option (right to buy) · traded 13 September 2021 · filed 15 September 2021
- exercised options over 998 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 415 September 2021Non-Qualified Stock Option (right to buy) · traded 14 September 2021 · filed 15 September 2021
- exercised options over 2 shares of Regeneron PharmaceuticalsSEC Form 415 September 2021Common Stock · traded 13 September 2021 · filed 15 September 2021
- ▼ sold on the open market 2 shares of Regeneron PharmaceuticalsSEC Form 415 September 2021Common Stock · traded 13 September 2021 · filed 15 September 2021
- exercised options over 998 shares of Regeneron PharmaceuticalsSEC Form 415 September 2021Common Stock · traded 14 September 2021 · filed 15 September 2021
- ▼ sold on the open market 998 shares of Regeneron PharmaceuticalsSEC Form 415 September 2021Common Stock · traded 14 September 2021 · filed 15 September 2021
- was granted 248 shares of Regeneron PharmaceuticalsSEC Form 45 January 2021Common Stock · traded 4 January 2021 · filed 5 January 2021
- was granted 3,613 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 45 January 2021Non-Qualified Stock Option (right to buy) · traded 4 January 2021 · filed 5 January 2021
- exercised options over 1,706 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 48 July 2020Non-Qualified Stock Option (right to buy) · traded 7 July 2020 · filed 8 July 2020
- exercised options over 1,706 shares of Regeneron PharmaceuticalsSEC Form 48 July 2020Common Stock · traded 7 July 2020 · filed 8 July 2020
- ▼ sold on the open market 1,706 shares of Regeneron PharmaceuticalsSEC Form 48 July 2020Common Stock · traded 7 July 2020 · filed 8 July 2020
- exercised options over 1,706 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 412 June 2020Non-Qualified Stock Option (right to buy) · traded 10 June 2020 · filed 12 June 2020
- exercised options over 1,706 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 412 June 2020Non-Qualified Stock Option (right to buy) · traded 11 June 2020 · filed 12 June 2020
- exercised options over 1,706 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 149 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 251 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 330 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 161 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 202 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 164 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 265 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 5 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 80 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▼ sold on the open market 99 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- exercised options over 1,706 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 11 June 2020 · filed 12 June 2020
- ▼ sold on the open market 1,706 shares of Regeneron PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 11 June 2020 · filed 12 June 2020
- exercised options over 5,118 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 48 May 2020Non-Qualified Stock Option (right to buy) · traded 7 May 2020 · filed 8 May 2020
- exercised options over 5,118 shares of Regeneron PharmaceuticalsSEC Form 48 May 2020Common Stock · traded 7 May 2020 · filed 8 May 2020
- ▼ sold on the open market 1,722 shares of Regeneron PharmaceuticalsSEC Form 48 May 2020Common Stock · traded 7 May 2020 · filed 8 May 2020
- ▼ sold on the open market 2,128 shares of Regeneron PharmaceuticalsSEC Form 48 May 2020Common Stock · traded 7 May 2020 · filed 8 May 2020
- ▼ sold on the open market 646 shares of Regeneron PharmaceuticalsSEC Form 48 May 2020Common Stock · traded 7 May 2020 · filed 8 May 2020
- ▼ sold on the open market 609 shares of Regeneron PharmaceuticalsSEC Form 48 May 2020Common Stock · traded 7 May 2020 · filed 8 May 2020
- ▼ sold on the open market 13 shares of Regeneron PharmaceuticalsSEC Form 48 May 2020Common Stock · traded 7 May 2020 · filed 8 May 2020
- was granted 4,361 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 46 January 2020Non-Qualified Stock Option (right to buy) · traded 2 January 2020 · filed 6 January 2020
- was granted 320 shares of Regeneron PharmaceuticalsSEC Form 46 January 2020Common Stock · traded 2 January 2020 · filed 6 January 2020
- was granted 3,784 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 44 January 2019Non-Qualified Stock Option (right to buy) · traded 2 January 2019 · filed 4 January 2019
- was granted 323 shares of Regeneron PharmaceuticalsSEC Form 44 January 2019Common Stock · traded 2 January 2019 · filed 4 January 2019
- was granted 7,439 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 43 January 2018Non-Qualified Stock Option (right to buy) · traded 2 January 2018 · filed 3 January 2018
- was granted 2,438 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 44 January 2017Non-Qualified Stock Option (right to buy) · traded 3 January 2017 · filed 4 January 2017
- was granted 15,353 shares of Regeneron Pharmaceuticals (a derivative holding)SEC Form 412 September 2016Non-Qualified Stock Option (right to buy) · traded 9 September 2016 · filed 12 September 2016
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.